Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2019 - Usefulness of bone modifying agents for non-weight bearing bone metastasis in breast cancer.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Breast Cancer

Presenters

KENGO KAWAGUCHI

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

K. KAWAGUCHI1, M.A.H.M. Latif2, K. Hayashi2, S. Ogita3

Author affiliations

  • 1 Orthopedic Surgery, Iizuka Hospital, 820-0018 - Iizuka/JP
  • 2 Statistics, St. Luke's international university, 1040044 - Tokyo/JP
  • 3 Medical Oncology, St. Luke's international hospital, 1048560 - Tokyo/JP
More

Resources

Abstract 2019

Background

Bone metastasis is common in breast cancer. No previous study evaluated the usefulness of bone modifying agents (BMA) in breast cancer patients whose metastases are limited to non-weight bearing bones.

Methods

We retrospectively collected data at St. Luke’s International Hospital between 2006 and 2016. Weight bearing bones were defined as vertebral body, lower limbs, and pelvis, and all the other bones were defined as non-weight bearing bones. Breast cancer patients, age ≥20 years old, who were newly diagnosed to have bone metastasis only in non-weight bearing bones were included in this study. Bone metastases were detected by either bone scintigraphy or PET-CT. The selected patients were divided into 2 groups: patients of Group A started BMA within 3 months from the diagnosis, and those of Group B did not start BMA within the 3 months. We are interested in comparing the Groups A and B in terms of time to skeletal related events (SRE) and overall survival (OS), where SRE were defined as orthopedic surgery, percutaneous vertebroplasty, and/or palliative radiation to bone metastasis.

Results

Out of 418 breast cancer patients with bone metastasis, only 101 patients were found to have bone metastasis only in non-weight bearing bones. The median follow-up time was 32 months. The number of patients in Group A and B were 54 and 47, respectively. Eight patients in Group A and 5 patients in Group B developed SRE (p = 0.568). Median SRE free survival (i.e. timeto SRE) was 118.5 months, and 117.3 months in Group A and Group B, respectively (p = 0.490, Hazard ratio: 1.48). Median overall survival (OS) was 39.7 months in group A and 78.3 months in group B (p = 0.203, Hazard ratio: 1.45).

Conclusions

Early initiation of BMA did not improve SRE free survival or OS in breast cancer patients who have only non-weight bearing bone metastasis. Further prospective studies are needed to confirm this finding.

Clinical trial identification

Legal entity responsible for the study

St. Luke's International Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.